English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51651824    線上人數 :  946
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"lu l c"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 31-40 / 144 (共15頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2022-02-07T07:49:00Z Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; SUNG-HSIN KUO; Hong R.-L.; Huang T.-C.; Yao M.
臺大學術典藏 2022-02-07T07:49:00Z Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma Yang S.-H.; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; SUNG-HSIN KUO; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; Yeh K.-H.
臺大學術典藏 2022-02-07T03:29:05Z Solving the deficit of cancer pain management skills by education programs Shao Y.-Y.; Lin W.-Y.; Lin C.-P.; Lu L.-C.; CHIH-HUNG HSU
臺大學術典藏 2022-02-07T03:29:04Z Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites Guo J.-C.; Lin C.-Y.; Lin C.-C.; Huang T.-C.; Lien M.-Y.; Lu L.-C.; Kuo H.-Y.; CHIH-HUNG HSU
臺大學術典藏 2022-02-07T03:29:03Z Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; CHIH-HUNG HSU; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L.
臺大學術典藏 2022-02-07T03:29:02Z Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance Wang Y.; Lu L.-C.; Guan Y.; Ho M.-C.; Lu S.; Spahn J.; CHIH-HUNG HSU
臺大學術典藏 2022-01-12T07:07:09Z Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience Wang Y.-W.; Tsai X.C.-H.; HSIN-AN HOU; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; Kuo S.-H.; Hong R.-L.; Huang T.-C.; Yao M.
臺大學術典藏 2022-01-05T03:36:40Z Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma Yang S.-H.; Lu L.-C.; Kao H.-F.; Chen B.-B.; Kuo T.-C.; Kuo S.-H.; Tien Y.-W.; Bai L.-Y.; Cheng A.-L.; KUN-HUEI YEH
臺大學術典藏 2022 ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis Lu L.-C.; Deantonio C.; Palu C.C.; Lee Y.-H.; Mitchell L.S.; Cowan M.; Corser M.; Sherry L.; Cheng A.-L.; Quaratino S.; Shao Y.-Y.; Sainson R.C.A.; CHIH-HUNG HSU
臺大學術典藏 2022 Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma Shao Y.-Y.; Cheng A.-L.; CHIH-HUNG HSU; Hsu C.; Lin Z.-Z.; Lu L.-C.; Chen B.-B.; Liang P.-C.; Shih T.T.-F.; Liu T.-H.; Shen Y.-C.

顯示項目 31-40 / 144 (共15頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目